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Myotonic dystrophy (DM) is the most common adult muscular 
dystrophy, characterized by autosomal dominant progressive my-
opathy, myotonia and multiorgan involvement. To date two dis-
tinct forms caused by similar mutations have been identified. My-
otonic dystrophy type 1 (DM1, Steinert’s disease) was described 
more than 100 years ago and is caused by a (CTG)n expansion 
in DMPK, while myotonic dystrophy type 2 (DM2) was identi-
fied only 18 years ago and is caused by a (CCTG)n expansion in 
ZNF9/CNBP. When transcribed into CUG/CCUG-containing 
RNA, mutant transcripts aggregate as nuclear foci that sequester 
RNA-binding proteins, resulting in spliceopathy of downstream 
effector genes. Despite clinical and genetic similarities, DM1 
and DM2 are distinct disorders requiring different diagnostic 
and management strategies. DM1 may present in four different 
forms: congenital, early childhood, adult onset and late-onset oli-
gosymptomatic DM1. Congenital DM1 is the most severe form 
of DM characterized by extreme muscle weakness and mental 
retardation. In DM2 the clinical phenotype is extremely vari-
able and there are no distinct clinical subgroups. Congenital and 
childhood-onset forms are not present in DM2 and, in contrast to 
DM1, myotonia may be absent even on EMG. Due to the lack of 
awareness of the disease among clinicians, DM2 remains largely 
underdiagnosed. The delay in receiving the correct diagnosis af-
ter onset of first symptoms is very long in DM: on average more 
than 5 years for DM1 and more than 14 years for DM2 patients. 
The long delay in the diagnosis of DM causes unnecessary prob-
lems for the patients to manage their lives and anguish with un-
certainty of prognosis and treatment.
Key words: Myotonic dystrophy type 1 (Dm1), myotonic dystro-
phy type 2 (Dm2), management
Introduction
Myotonic dystrophies (DMs) are autosomal domi-
nant, multisystemic diseases with a core pattern of clini-
cal presentation including myotonia, muscular dystrophy, 
cardiac conduction defects, posterior iridescent cataracts, 
cerebral involvement and endocrine disorders (1). In 
1909 Steinert and colleagues first clearly described the 
“classic” type of myotonic dystrophy which was called 
Steinert’s disease (OMIM 160900). The gene defect re-
sponsible for myotonic dystrophy described by Steinert 
was discovered in 1992 and found to be caused by ex-
pansion of a CTG repeat in the 3’ untranslated region of 
DMPK, a gene encoding a protein kinase (2-4). Subse-
quently, in 1994, a different multisystemic disorder was 
described with dominantly inherited myotonia, proximal 
greater than distal weakness, and cataracts but lacking the 
gene defect responsible for Steinert’s disease (5-7). In 
Europe, the disease was termed proximal myotonic myo-
pathy (PROMM, OMIM*160900) (6) or proximal myo-
tonic dystrophy (PDM) (7) while in the United States was 
termed myotonic dystrophy with no CTG repeat expan-
sion or myotonic dystrophy type 2 (DM2) (5). Later stud-
ies demonstrated that many of the families identified as 
having myotonic dystrophy type 2, PROMM or PDM had 
the same disease, a disorder caused by an unstable tetra-
nucleotide CCTG repeat expansion in intron 1 of Zinc fin-
ger protein 9 gene (ZNF9) mapped to 3q21.3 (8, 9). Due 
to the existence of different types of myotonic dystro-
phy, the International Myotonic Dystrophy Consortium 
developed a new nomenclature and guidelines for DNA 
testing  (10). The Steinert’s disease that results from an 
unstable trinucleotide repeat expansion on chromosome 
19, is now termed myotonic dystrophy type 1 (DM1). Pa-
tients with the clinical picture of myotonic dystrophy type 
2/proximal myotonic myopathy, who have positive DNA 
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testing for the unstable tetranucleotide repeat expansion 
on chromosome 3, are now classified as having myotonic 
dystrophy type 2 (DM2) (5, 11-12).
Although DM1 and DM2 have similar symptoms, 
they also present a number of very dissimilar features 
making them clearly separate diseases (Table 1).
Myotonic Dystrophy type 1
Clinical features 
Myotonic dystrophy type 1 is the most common in-
herited muscular dystrophy in adults with an estimated 
prevalence of 1/8000. DM1 is characterized by the phe-
nomenon of anticipation, by which the disease has an ear-
lier onset and more severe course in subsequent genera-
tions. Patients with DM1 can be divided into four main 
categories, each presenting specific clinical features and 
management problems: congenital, childhood-onset, 
adult-onset, and late-onset/asymptomatic. Table 2 sum-
marises these subtypes.
Congenital DM1
Congenital DM1 (CDM) shows a distinct clinical 
phenotype with distinct clinical features, therefore it is 
to be considered a severe early form of ‘classical’ DM1. 
CDM often presents before birth as polyhydramnios and 
reduced fetal movements. After delivery, the main fea-
tures are severe generalized weakness, hypotonia and 
respiratory involvement. In up to 50% of CDM, bilat-
eral talipes and other contractures are present at birth. 
One feature of affected infants is the “fish-shaped” up-
per lip, an inverted V-shaped upper lip which is char-
acteristic of severe facial weakness and causes weak 
cry and inability to suck. Mortality from respiratory 
failure is high. Surviving infants experience gradual 
improvement in motor function, they can swallow and 
independently ventilate. Almost all CDM children are 
able to walk. Cognitive and motor milestones are de-
layed and all patients with CDM develop learning dif-
ficulties and require special needs schooling. Cerebral 
atrophy and ventricular enlargement are often present 
Table 1. Comparison of clinical manifestations between DM1 and DM2.
Clinical Features DM1 DM2
General features
Epidemiology
Age of onset (years)
Anticipation
Congenital form
Life expectancy
Widespread
0 to adult
Always present
Present
Reduced
European
8-60 
Exceptional
Absent
Normal range
Core features
Clinical myotonia
EMG myotonia
Muscle weakness
Cataracts
Evident in adult- onset
Always present
Disabling at age 50
Always present
Present in <50%
Absent or variable in many
Onset after age 50-70
Present in minority
Muscle symptoms
Facial and jaw weakness
Bulbar weakness-dysphagia
Respiratory muscles weakness
Distal limb muscle weakness
Proximal limb muscle weakness
Sternocleidomastoid weakness
Myalgic pain 
Visible muscle atrophy
Calf hypertrophy
Always present
Always later
Always later
Always prominent
May be absent
Always prominent
Absent or mild
Face, temporal, distal hands and legs
Absent
Usually absent
Absent
Exceptional
Only flexor digitorium profundus, rare
Main disability in most patients, late
Prominent in few
Most disabling symptom in many
Usually absent
Present in ≥50%
Systemic features
Tremors 
Behavioral change
Cognitive disorders
Hypersomnia
Cardiac arrhythmias 
Male hypogonadism
Manifest diabetes 
Absent
Early in most
Prominent
Prominent
Always present
Manifest
Frequent
Prominent in many
Not apparent
Not apparent
Infrequent
From absent to severe
Subclinical in most
Infrequent
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Adult onset DM1
The core features in classic DM1 are distal muscle 
weakness, leading to difficulty with performing tasks 
requiring fine dexterity of the hands and foot drop, and 
facial weakness and wasting, giving rise to ptosis and 
the typical myopathic or ‘hatchet’ appearance. The neck 
flexors and finger/wrist flexors are also commonly in-
volved. Grip and percussion myotonia are regular fea-
tures; however, myotonia affects other muscle including 
bulbar, tongue or facial muscles, causing problems with 
talking, chewing, and swallowing. Elevation of the se-
rum creatine kinase is present. Cardiac involvement is 
common in DM1 and includes conduction abnormali-
ties with arrhythmias and conduction blocks contribut-
ing significantly to the morbidity and mortality of the 
disease (19-22). In some patients and families, a dilated 
cardiomyopathy may be observed. Posterior subcapsu-
lar cataracts develop in most patients, in some of them 
at an early age without any other muscle symptoms 
which will develop later in their disease (23). Minor 
intellectual deficits are present in many patients in con-
trast with CDM and childhood onset DM1. Avoidant, 
obsessive-compulsive and passive-aggressive personal-
ity features have also been reported (24, 25). Nocturnal 
apnoeic episodes and daytime sleepiness are a common 
manifestation. Gastrointestinal tract involvement covers 
irritable bowel syndrome, symptomatic gall stones and 
gamma-glutamyltransferase elevations. Finally, endo-
at birth (13, 14). A progressive myopathy and the other 
features seen in the classical form of DM1 can develop 
although this does not start until early adulthood and 
usually progresses slowly (15). Despite the severe mus-
cular phenotype, clinical myotonia is neither a feature 
presented in the neonatal period nor can it be disclosed 
in the electromyogram (EMG). Patients often develop 
severe problems from cardio-respiratory complications 
in their third and fourth decades.
Childhood onset DM1
The diagnosis of this form of DM1 is often missed 
in affected adolescents or children because of unchar-
acteristic symptoms for a muscular dystrophy and ap-
parently negative family history (16). Cases of DM1 
that come to medical attention during childhood typi-
cally manifest developmental abnormalities that are less 
severe than seen in congenital onset cases (17). Unlike 
the CDM patients, in which maternal transmission is the 
rule, the sex of the parents does not influence the devel-
opment of childhood onset DM1. These patients have 
cognitive deficits and learning abnormalities (18). As in 
the congenital cases, degenerative features often devel-
op as these children reach adulthood. There is increasing 
evidence of early conduction abnormalities, and from 
the age of 10, annual electrocardiograms and considera-
tion of electrophysiological studies should be a part of 
routine management.
Table 2. Summary of myotonic dystrophy type 1 phenotypes, clinical findings and CTG length.
Phenotypes Clinical findings CTG length Age of onset
Congenital
Infantile hypotonia
Respiratory failure
Learning disability
Cardiorespiratory complications
> 1000 Birth
Childhood onset
Facial weakness
Myotonia
Low IQ
Conduction defects
50-1000 1-10 years
Adult onset
“classic DM1”
Weakness
Myotonia
Cataracts
Conduction defects
Insulin resistance
Respiratory failure
50-1000 10-30 years
Late onset/
Asymptomatic
Mild myotonia
Cataracts 50-100 20-70 years
Pre-mutation None 38-49 N/A
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adult-onset severe form to very late–onset mild symp-
toms (paucisymptomatic).
Clinically based ascertainment of DM2 patients is 
even more difficult because of the large phenotypic vari-
ability and a large number of individuals with milder 
symptoms who remain undiagnosed. Moreover, milder 
phenotypes with prominent myalgia may easily be mis-
diagnosed as fibromyalgia (29) and patients with onset of 
slowly progressive proximal muscle weakness after age 
70 years may not be referred for neuromuscular investi-
gations. Further evidence that a large proportion of DM2 
patients may be undiagnosed came from a recent study 
which indicate that co-segregation of heterozygous reces-
sive CLCN1 mutations in DM2 patients is higher than ex-
pected (30). In DM2 patients with co-segregating CLCN1 
the severity of myotonia appear to be more evident ei-
ther clinically or on EMG, thus these patients could be 
more easily identified and diagnosed than DM2 patients 
without the modifier allele. Consequently the majority of 
DM2 patients remains undiagnosed even in clinical cent-
ers with considerable experience with DM2.
DM2/PROMM typically appears in adult life and 
has variable manifestations, such as early-onset cataracts 
(younger than 50 years), varying grip myotonia, thigh 
muscle stiffness, and muscle pain, as well as weakness 
(hip flexors, hip extensors, abdominal muscles, or long 
flexors of the finger muscles) (5, 6, 11, 12, 31-34). These 
complaints often appear between 20 and 70 years of age, 
and patients as well as their care providers ascribe them to 
crine abnormalities include testicular atrophy, hypotes-
tosteronism, insulin resistance with usually mild type-2 
diabetes, thyroid dysfunction. 
Late-onset/asymptomatic DM1
In late-onset or asymptomatic patients (with low 
number of CTG repeats), only limited features are found 
on clinical and paraclinical assessment. Myotonia, weak-
ness and excessive daytime sleepiness are rarely present. 
Before DNA tests became available, there were many 
examples of incorrect ascertainment, even when using 
markers such as EMG evidence of myotonia and slit-
lamp examination for the characteristic cataracts (26). In 
late-onset patients, the search for cataracts is helpful for 
identifying the transmitting person.
Myotonic Dystrophy type 2
Clinical features 
The prevalence of DM2 is not well established, but 
estimated to be similar to DM1 in European popula-
tions (27). In DM2 there are no distinct clinical subgroups 
although initially different phenotypes of DM2 were de-
scribed: DM2/PROMM and PDM (5-7). The most im-
portant discrepancy between DM1 and DM2 is absence 
of a congenital or early-onset form in DM2 (12, 28) and 
the clinical presentation is a more continuum from early 
Table 3. Muscle histopatology in DM1 and DM2.
Histopathological findings DM1 DM2
Fiber size variation +++ +++
Internal nuclei +++ +++
 more in type 2 fibers
Type 1 fiber atrophy ++ -
Type 2 fiber atrophy + ++
Type 2 fiber hypertrophy - +
Nuclear clump fibers +at advanced stages only
+++
more in advanced stages
Atrophic fibers (diam. ≤ 6µm)
±
type 1 and type 2 fibers
at advanced stages only
+++
type 2 fibers
Ring fibers ++ +
Sarcoplasmic masses ++ ±
Fibrosis +++at late stages only
++
at late stages only
Fatty replacement +++at late stages only
++
at late stages only
+++ present in >75% of biopsies; ++ present in 20-50% of biopsies; + present in 10-24% of biopsies; ± occasionally present; - absent
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12.000 bp) and is nearly always associated with symp-
tomatic disease although there are patients who have up 
to 60 repeats who are asymptomatic into old age and 
similarly patients with repeat sizes up to 500 who are 
asymptomatic into middle age. Normal individuals have 
between 5 and 37 CTG repeats. Patients with between 
38 and 49 CTG repeats are asymptomatic but are at risk 
of having children with larger, pathologically expanded 
repeats (5). This is called a ‘pre-mutation’ allele. The 
DM1 mutation length predicts the clinical outcome to 
some extent: classical DM1 100-1.000 repeats; congeni-
tal > 2.000 repeats (10, 45). DM2 results from an unstable 
tetranucleotide repeat expansion, CCTG, in intron 1 of 
the nucleic acid-binding protein (CNBP) gene (previous-
ly known as zinc finger 9 gene, ZNF9) on chromosome 
3q21 (8, 9). The size of the CCTG repeat is below 30 
repeats in normal individuals while the range of expan-
sion sizes in DM2 patients is huge. The smallest reported 
mutation vary between 55-75 CCTG (9, 46) and the larg-
est expansions have been measured to be up about 11.000 
repeats (9). Both DM1 and DM2 mutations show instabil-
ity with variation in different tissue and cell types caus-
ing somatic mosaicism (47, 48). The size of the CTG and 
CCTG repeat appear to increase over time in the same 
individual, and are dynamic gene defects (12). However 
DM1 children may inherit repeat lengths considerably 
longer than those present in the transmitting parent. This 
phenomenon causes anticipation, which is the occurrence 
of increasing disease severity and decreasing age of onset 
in successive generations. A child with congenital DM1 
almost always inherits the expanded mutant DMPK allele 
from their mother. However anticipation may be seen in 
patients with DM1 who inherit a smaller expanded CTG 
repeat from their father (49, 50). In DM2 the mutation 
usually contracts in the next generation, being shorter in 
children (12). This may explains some distinct features of 
DM2 such as the missing of a congenital form, the lack 
of anticipation and the later onset (28). The size of CCTG 
repeat expansion in leukocyte DNA in DM2 seems to re-
late in large part to the age of the patient and not neces-
sarily to the severity of symptoms or manifestations. This 
complicates attempts to correlate the size of the repeat 
with earlier clinical onset of more severe symptoms as 
occurs in patients with DM1. However due to somatic 
mosaicism, CTG repeat size correlates more significantly 
with age of onset and disease severity below 400 CTG 
repeats (51). The correlation between CTG repeat size 
and the severity of the disease can be observed in blood 
but not in other organs (eg, muscle). In DM1 the repeat 
lengths in muscle are shown to be larger (52) and there 
is no correlation between the size of the CTG repeats in 
muscle and the degree of weakness. It should be noted 
that in clinical practice, the CTG expansion is measured 
overuse of muscles, “pinched nerves,” “sciatica,” arthritis, 
fibromyalgia, or statin use (35). Early in the presentation 
of DM2 there is only mild weakness of hip extension, thigh 
flexion, and finger flexion. Myotonia of grip and thigh 
muscle stiffness varies from minimal to moderate sever-
ity over days to weeks. Myotonia is often less apparent in 
DM2 compared with patients with DM1. It is more dif-
ficult to elicit myotonia on standard EMG testing in DM2 
compared to DM1 except for proximal muscles such as 
the tensor fascia lata and vastus lateralis muscles. In cases 
of late-onset DM2, myotonia may only appear on electro-
myographic testing after examination of several muscles 
(32). Facial weakness is mild in DM2 as is muscle wasting 
in the face and limbs. The cataracts in DM2 have an ap-
pearance identical to that observed in DM1 and develop 
before 50 years of age as iridescent, posterior capsular 
opacities on slit-lamp. Cardiac problems appear to be less 
severe and frequent in patients with DM2 than in patients 
with DM1 (36, 37). In DM2, cardiac conduction alterations 
are primarily limited to first-degree atrio-ventricular and 
bundle branch block. However, sudden death, pacemaker 
implantation, and severe cardiac arrhythmias have been de-
scribed in small numbers of patients (33, 38). In DM2, no 
ventilatory insufficiency has been reported. Central nerv-
ous system involvement represents one of the major dif-
ferences between DM1 and DM2. Although retarded DM2 
individuals have been reported, these occurrences may be 
either accidental or an infrequent disease consequence (12, 
31). The type of cognitive impairment that occurs in DM2 
is similar to but less severe than that of DM1. Other mani-
festations, such as hypogonadism, glucose intolerance, 
excessive sweating, and dysphagia, may also occur and 
worsen over time in DM2 (5, 11, 12, 34, 39, 40, 41, 42, 43). 
Pregnancy and menses may also exacerbate muscle pain, 
myotonia, and muscle cramps (44). PDM patients show 
many features similar to those found in PROMM, includ-
ing proximal muscle weakness, cataracts, and electro-
physiologically detectable myotonia. Unlike PROMM pa-
tients, however, they do not report myalgias, symptomatic 
myotonia, or muscle stiffness. Instead they present traits 
not present in PROMM, such as pronounced dystrophic-
atrophic changes in the proximal muscles and late-onset 
progressive deafness (7). 
Genetics
The DM1 mutation was identified in 1992 as an ex-
pansion of an unstable CTG trinucleotide repeat in the 
3’untranslated region (UTR) of the myotonic dystrophy 
protein kinase gene (DMPK; OMIM 605377) which 
codes for a myosin kinase expressed in skeletal muscle. 
The gene is located on chromosome 19q13.3 (3, 4). In 
DM1 patients the repeat size range from 50-4.000 (150-
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Misregulation of alternative splicing plays a central role 
in the development of important DM symptoms (58, 60). 
For example, among the symptoms of DM, myotonia, 
insulin resistance and cardiac problems are correlated 
with the disruption of the alternative splicing of the 
muscle chloride channel ClC-1, of the insulin receptor 
(IR) and of the cardiac troponin T (TNNT3), respec-
tively (41, 43, 65, 66, 67). However, spliceopathy may 
not fully explain the multisystemic disease spectrum. The 
underlying mechanism responsible for muscle weakness 
and wasting remains to be established. Recent findings 
suggest that DM mutations can affect gene expression 
in multiple ways. Altered activity and/or localization of 
MBNL1 and CELF1 may alter transcription, translation 
and cell signaling (68, 69). Moreover it has been dem-
onstrated that in DM1 the highly regulated pathways of 
miRNA is altered in skeletal muscle and heart tissue po-
tentially contributing to DM1 pathogenetic mechanisms 
and in DM2 skeletal muscle (70-73). Another open ques-
tion in the field of DM is to clarify the pathomecanisms 
underlying the phenotypic differences between DM1 and 
DM2. Clinical signs in DM1 and DM2 are similar, but 
there are some distinguishing features: DM2 is generally 
less severe and lacks a prevalent congenital form. This 
suggests that other cellular and molecular pathways are 
involved besides the shared toxic-RNA gain of function 
hypothesized. Disease-specific manifestations may result 
from differences in spatial and temporal expression pat-
terns of DMPK and CNBP genes. Similarly, changes in 
the expression of neighbouring genes may define disease-
specific manifestations. Importantly, the role of CELF1 in 
DM2 is particularly intriguing with contradictory results 
being reported (54, 59, 62). Another possible explanation 
for the clinical differences between the two DM forms is 
the reduction of DMPK or ZNF9 protein levels in DM1 
and DM2 respectively (3, 74-76). Indeed both knockout 
mouse models for DMPK and ZNF9 show the phenotypic 
aspects of DM (77, 78). Taken together these observa-
tions seem indicate that the emerging pathways of molec-
ular pathogenesis are far more complex than previously 
appreciated.
Diagnostics
Laboratory tests
As for all genetics diseases with identified mutation, 
the typical DM1 and DM2 diagnostic method is mutation 
verification by genetic tests. In the case of DM1, symp-
toms and family history are often clear and distinctive 
enough to make a clinical diagnosis, and the mutation can 
be confirmed by PCR and Southern Blot analysis. PCR 
analysis is used to detect repeat lengths less than 100 and 
in blood and there is no additional clinical advantage of 
measuring repeat size in muscle.
Molecular pathomechanism 
As described above the two types of the disease are 
associated with two different loci: DM1 is caused by the 
expansion of an unstable CTG trinucleotide repeat in the 
3′ UTR of the DMPK gene (2, 4) while DM2 mutation 
consists in the expansion of an unstable CCTG tetranu-
cleotide within the first intron of the nucleic acid-binding 
protein (CNBP) gene (previously known as zinc finger 9, 
ZNF9) (9). The fact that two repeat sequences located in 
entirely different genes can cause such similar disease 
features implies a common pathogenic mechanism. It 
is now clear that the gain-of-function RNA mechanism 
is the predominant cause of pathogenesis of myotonic 
dystrophies in which the expansion mutation, (CTG)n in 
DM1 and (CCTG)n in DM2, is transcribed and the mutant 
RNAs containing the repeat expansions accumulate in the 
cell nuclei as foci, called ribonuclear inclusions, and are 
responsible for the pathologic features common to both 
disorders. The expanded CUG/CCUG-containing tran-
scripts form hairpins, imperfect double-stranded structure 
which lead to deregulation of two important RNA-bind-
ing proteins, muscleblind–like protein 1 (MBNL1) and 
CUGBP/Elav-like family member 1 (CELF1). In DM1, 
MBNL1 protein is depleted from the nucleoplasm through 
recruitment into ribonuclear foci (53, 54, 55) while CELF1 
stabilization by PKC phosphorylation results in increased 
steady-state levels and protein upregulation (56). Recently 
over-expression of CUGBP1 in skeletal muscle from adult 
DM1 but not from DM2 has been described (57). A com-
bined effect of decreased MBNL1 and increased CELF1 
activity lead to misregulated alternative splicing and other 
changes of the muscle transcriptome (58, 59). The altera-
tion of pre-mRNA processing strengthens the hypothesis 
of a spliceopathy which leads to inappropriate expres-
sion of embryonic splicing isoforms in adult tissues (60). 
In DM2, splicing abnormalities are also associated with 
the sequestration of MBNL1 protein by expanded tran-
scripts (58, 61). However evidence that CUGBP1 upregu-
lation also occurs in DM2 is conflicting (54, 59, 62). How-
ever in a recent paper (57) we have shown a normal level 
of CUGBP1 in a large cohort of Italian DM2 patients. 
Recent data demonstrate that MBNL1-containing foci in 
DM2 cells also sequester snRNPs and hnRNPs, splicing 
factors involved in the early phases of transcript process-
ing, thus strengthening the hypothesis that a general al-
teration of pre-mRNA post-transcriptional pathway could 
be at the basis of the multifactorial phenotype of DM2 
patients (63, 64). 
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modified Southern method using field–inversion electro-
phoresis (FIGE) is particularly efficient in determining 
the mutation length (82). However, these methods are still 
too long and complicated to be part of routine laboratory 
diagnostics. Nevertheless ribonuclear foci and splicing 
changes are present before any histological abnormality 
manifestations (43, 83). This could be important for an 
early diagnosis before the spectrum of clinical signs of 
muscle disease appear. So a more practical tool to obtain 
a definitive DM2 diagnosis in few hours is represented by 
in situ hybridization (ISH) which is a method that allows 
the direct visualization of the mutant RNA on muscle bi-
opsy (84, 85). By using specific probes for CCUG expan-
sions, it permits a differential diagnosis between DM2 
and DM1. Therefore it may be a simple approach for 
DM2 diagnosis, which can be performed in a rapid and 
sensitive manner in any pathology laboratory. ISH with 
CAGG probe should be considered as a routine labora-
tory procedure to confirm or refute the clinical suspicion 
of DM2. It should also be applied routinely to screen pa-
tients with myotonic disorders (84, 85). This approach 
makes muscle biopsy an essential tool for DM2 diagno-
sis (Fig. 1A). Moreover, since MBNL1 is sequestered by 
mutant RNA foci, it is possible to visualize the nuclear 
accumulation of MBNL1 by immunofluorescence on 
muscle sections (Fig. 1B). However, although MBNL1 
represents an histopathological marker of DM, it does not 
allow to distinguish between DM1 and DM2 (86). 
Muscle biopsy
The histological features of muscle in DM1 and DM2 
are very similar (Fig. 2), and sufficiently characteristic so 
that a diagnosis of DM can be suggested based on muscle 
Southern blot analysis to detect larger expansions. Pre-
dictive testing in asymptomatic relatives as well as prena-
tal and preimplantation diagnosis can also be performed.
On the contrary, the wide clinical spectrum of DM2 
phenotype makes the clinical diagnosis more difficult. 
Moreover conventional PCR and Southern blot analysis 
are not adequate for a definitive molecular diagnosis in 
DM2 due to the extremely large size and somatic insta-
bility of the expansion mutation (9, 46). The copy num-
ber of DM2 CCTG is below 30 in phenotypically normal 
individuals and up 11.000 in patients (79). A complex 
genotyping diagnostic procedure is now commonly used 
consisting of a three step molecular protocol (12, 28): (A) 
a conventional PCR assay across the mutation locus us-
ing probes binding to mutation flanking sequences can be 
used for mutation exclusion. In all DM2 patients, a single 
PCR product representing the normal allele can be identi-
fied because the DNA polymerase fail to amplify the mu-
tant allele due to length and stable secondary structure. 
All individuals showing two alleles for the marker are ex-
cluded from having the DM2 mutation. However, identi-
cal allele size on two normal alleles occurs in 12% of the 
population; (B) all patients appearing to have one allele 
need further molecular analysis to determine whether or 
not they carry a DM2 expansion. Because of the incom-
plete sensitivity of Southern analysis, a DM2 repeat as-
say (RP-PCR) was developed; (C) the RP-PCR method 
involves amplifying the CCTG repeat by PCR, and prob-
ing the resultant product with an internal probe to assure 
specificity. The combined use of these methods allows 
99% sensitivity and specificity for known expansions. 
Several alternative and highly sensitive methods have 
been developed for DM2 mutation verification including 
long-range PCR (80) and a tetraplet-primed PCR (81). A 
Figure 1. Fluorescence in situ hybridization (FISH) in combination with MBNL1-immunofluorescence on DM2 muscle 
section. A. Visualization of (CCTG)n expansion on muscle section by FISH using (CAGG)5 specific probe. Red spots 
within myonuclei (blue, DAPI) represent ribonuclear inclusions containing accumulated mutant RNAs. B. Visualization 
of nuclear foci of MBNL1 (green spots) colocalizing with ribonuclear inclusions in A.
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Figure 2. Panel showing muscle histology in DM1 and DM2. A-C. Transversal sections from DM1 muscle biopsies. A. 
Haematoxylin & Eosin: fiber size variation and central nuclei (arrows) are present. B, C. The population of atrophic fibers 
(white arrow) are preferentially type 1 fibers as demonstrated in sections stained for ATPase pH 4.3 (B, dark brown) or 
immunostained for myosin MHCslow (C, brown). Black arrow indicate centrally located nuclei. D-E Transversal sections 
from DM2 muscle biopsies. D. Haematoxylin & Eosin: as in DM1 muscle, fiber size variation and central nuclei (arrows) 
are present. Abundant nuclear clumps are also present (arrow heads) despite the muscle shows an early stage pathol-
ogy. E, F. Type 2 fibers are predominantly affected in DM2 muscle: in routine laboratory muscle staining such as ATPase 
pH 10.0 (E) or immunostaining for myosin MHCfast (F), type 2 fiber atrophy (white arrows) and type 2 central nucleation 
(black arrow) are commonly observed. 
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for DM1. A frequent and difficult problem in DM2 is the 
peculiar muscle pain described earlier (35, 29). The ex-
act mechanism underlying the pain is unknown, and there 
is no well-established, effective treatment. Carbamazepine 
or mexiletine along with nonsteroidal anti-inflammatory 
medications or tylenol ameliorate this pain in some pa-
tients.
Concluding remarks
The myotonic dystrophies are dominantly inherited 
multisystemic disorders that include two genetically 
distinct types. DM1 is the commonest cause of adult 
onset muscular dystrophy with an estimated prevalence 
of 1/8000. Due to the lack of awareness of the disease 
among clinicians, DM2 remains largely underdiagnosed 
and the prevalence of DM2 is not well established. 
These diseases have been called ‘spliceopathies’ and 
are mediated by a primary disorder of RNA rather than 
proteins, however, spliceopathy may not fully explain 
the multisystemic disease spectrum. Although the two 
forms of myotonic dystrophy share many features, there 
are definite differences with respect to clinical, muscle 
biopsy, and genetic findings. In DM2 the core symptoms 
include proximal muscle weakness, myotonia, cataracts, 
cardiac conduction defects, insulin resistance and male 
hypogonadism. In DM1, the muscle weakness and wast-
ing are more severe, preferentially distal and facial with 
ptosis, and with later evolving dysphagia, generalized 
weakness, and respiratory failure. A severe congenital 
form associated with DM1 has not been observed in 
DM2, and anticipation is the exception in DM2. In con-
trast to DM1, type 2 fiber are preferentially involved in 
DM2 with the presence of very atrophic type 2 fibers 
early in muscle pathogenesis. The basis for the differ-
ences between DM1 and DM2 has not been clarified 
at the molecular level. There is currently no cure but 
effective management is likely to significantly reduce 
the morbidity and mortality of patients. The enormous 
advances in the understanding of the molecular patho-
genesis of DM1 and DM2 has revealed pathways of 
molecular pathogenesis more complex than previously 
appreciated that could be the right track towards the de-
velopment of effective therapies. 
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biopsy alone (1, 12, 87). In both diseases, affected mus-
cles show a high number of central nuclei and a mark-
edly increased variation in fiber diameter that commonly 
ranges from less than 10 µm to greater than 100 µm (Fig. 
2A, D). Basophilic regenerating fibers, splitting fibers, fi-
brosis and adipose deposition occur in both diseases to 
a variable degree depending on the extent of muscle in-
volvement. Ring finger fibers and sarcoplasmic masses 
are generally more frequent in DM1 muscle biopsy. Re-
cently the comparison of muscle biopsy findings in clas-
sic DM1 with those in DM2 has indicated that specific 
features are present in DM2 muscle biopsy helping the 
diagnosis of DM2. Severely atrophic fibers with pyknot-
ic nuclear clumps similar in appearance to the severely 
atrophic fibers in neurogenic atrophy are frequently 
found in DM2 biopsy also before the occurrence of mus-
cle weakness (Fig. 2D). In DM1, nuclear clumps are pre-
sent in end-stage muscle biopsy (88). A predominant type 
2 fiber atrophy in contrast to the type 1 atrophy observed 
in DM1, has been described in DM2 (87, 89, 90, 91) (Fig. 
2B,C,E,F). Moreover, in DM2 muscle biopsy central nu-
cleation selectively affects type 2 fibers and the atrophic 
nuclear clumps express fast myosin isoform (type 2 fiber) 
indicating that DM2 is predominantly a disease of type 2 
myofibers (90) (Fig. 2F; Table 3).
Management
In general the management of DM2 is similar to that 
of DM1, but there is less need for supportive care, such 
as bracing, scooters, or wheelchairs. Cataracts require moni-
toring. Cardiorespiratory disorders are responsible for 
70% of the mortality in DM1 and many of these patients 
could have been treated by active monitoring and a lower 
threshold for input. Disturbances in cardiac rhythm are less 
frequent in DM2, but abnormalities do occur (121, 36-38), 
and serial monitoring with an electrocardiogram is nec-
essary to check for covert dysrhythmia. Hypogonadism 
and insulin resistance need monitoring in both diseases. 
Myotonia tends to be less marked and less troublesome 
in DM2, but in specific circumstances antimyotonia ther-
apy is helpful, especially if muscle stiffness is frequent 
and persistent or if pain is prominent (92). Cognitive 
difficulties also occur in DM2 as in DM1 but become 
manifest in adult life and appear to be associated with 
decreased cerebral blood flow to frontal and anterior tem-
poral lobes (39, 93) and decreased brain volume  (94, 95). 
The changes are less severe than in DM1. Their aetiol-
ogy is unknown but may relate to the toxic effect of in-
tranuclear accumulations of abnormally expanded RNA. 
Management of these brain symptoms is similar to that 
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